secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cue Biopharma, Inc. (CUE)
CIK:        0001645460
Form:       8-K
Filed at:   2024-07-25T23:59:59+00:00
Accession:  0000950170-24-086476
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cue Biopharma restructures, cuts workforce 25%, extends cash runway to mid-2025
-------------------------------------------------------------------------------

- Reduces workforce by ~25% across R&D and G&A; CEO Daniel Passeri takes 50% salary reduction, execs forgo 2023 bonuses.
- Prioritizes autoimmune programs CUE-401 (partnered with Ono) and CUE-501; retains oncology CUE-101/102 Phase 1 data maturation.
- Projects FY2025 annual cash burn of ~$30M, an ~25% reduction in operating expenses.
- Expects extended cash runway into mid-2025; actively pursuing partnerships for oncology programs.
- Restructuring effective July 24, 2024; aims to reduce capital requirements and strengthen operational efficiencies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645460/000095017024086476/0000950170-24-086476-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645460/000095017024086476/cue-20240724.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-086476

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer